This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Bictegravir with emtricitabine and tenofovir alafenamide oral


Oral formulations of bictegravir with emtricitabine and tenofovir alafenamide.

Drugs List

  • bictegravir 50mg and emtricitabine 200mg and tenofovir alafenamide 25mg film coated tablets
  • BIKTARVY 50mg+200mg+25mg film coated tablets
  • Therapeutic Indications


    Treatment of HIV infected adults

    Adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.



    One tablet once daily.

    Additional Dosage Information

    If a dose is missed, take the prescribed dose as soon as possible, but within 18 hours of the time it is usually taken. The dose should not be taken if a missed dose is noticed more than 18 hours after the time it is usually taken.


    Children under 18 years
    Renal impairment - creatinine clearance below 30 ml/minute
    Severe hepatic impairment

    Precautions and Warnings

    Hepatic impairment
    Hepatitis B
    Hepatitis C

    Discontinuation of treatment may exacerbate hepatitis in HBV co-infection
    Monitor HBV levels during and after treatment in patients with co-infection
    Treatment does not prevent risk of transmission of HIV
    Advise ability to drive/operate machinery may be affected by side effects
    Treatment should be initiated by doctor experienced in HIV management
    Autoimmune disorders can occur many months after initiation of treatment
    Blood lipid and glucose levels may increase requiring treatment
    Monitor closely patient with pre-existing hepatic impairment
    On discontinuation, may cause recurrence of hepatitis B
    Advise patient to seek medical advice if joint aches or pain occur
    Advise patient to seek medical advice if movement becomes difficult
    Inflammatory symptoms should be evaluated and treated appropriately
    May cause weight gain
    May develop immune reactivation syndrome
    Neonate exposed in utero: Risk of mitochondrial dysfunction
    Prolonged use may lead to nephrotoxicity
    Discontinue if hepatic function deteriorates in pts with hepatic impairment
    Advise patient not to take St John's wort concurrently
    Advise to avoid antacids/mineral supplements 2 hours before or after dose
    Take another dose if vomiting occurs within one hour

    Patients co-infected with hepatitis B or C are at an increased risk of severe, potentially fatal hepatic adverse events. When discontinuing treatment with bictegravir with emtricitabine and tenofovir alafenamide in patients co-infected with hepatitis B and HIV, monitor closely for several months after treatment.

    Blood lipid and glucose levels may increase during antiretroviral therapy. This may be linked to disease control and lifestyle. Refer to established HIV treatment guidelines for monitoring and manage lipid and glucose level disorders as appropriate.

    When combination antiretroviral therapy is initiated in HIV-infected patients with severe immune deficiency, an inflammatory reaction to asymptomatic or residual opportunist pathogens may arise. This can lead to the aggravation of symptoms or other serious clinical conditions such as cytomegalovirus retinitis, mycobacterial infections or Pneumocystis jirovecii pneumonia. These reactions are usually observed within the first few weeks or months after treatment initiation. Any inflammatory symptoms should be evaluated and treated appropriately.

    Treatment regimens containing nucleoside or nucleotide analogues have been reported to cause mitochondrial dysfunction in HIV-negative infants exposed in utero and/or post-natally. Adverse reactions such as haematological (anaemia, neutropenia), metabolic (hyperlactataemia, hyperlipasemia) and neurological (hypertonia, convulsions, abnormal behaviour) have been reported. Consider in children exposed to nucleoside or nucleotide analogues in utero (including HIV-negative infants) and who present with neurological symptoms or severe clinical findings of unknown cause.

    Bictegravir with emtricitabine and tenofovir alafenamide should be avoided but may be used in adults with end stage renal disease on chronic haemodialysis if the potential benefits outweigh the potential risks. In a study of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet in HIV-1 infected adults with end stage renal disease on chronic haemodialysis, efficacy was maintained through 96 weeks but emtricitabine exposure was significantly higher than in patients with normal renal function. No additional adverse reactions were identified, the implications of increased emtricitabine exposure remain uncertain.

    Pregnancy and Lactation


    Use bictegravir with emtricitabine and tenofovir alafenamide with caution during pregnancy.

    The manufacturer advises bictegravir with emtricitabine and tenofovir alafenamide may be used only if the benefit justifies the potential risk to the foetus. Animal studies have shown no increased risk of teratogenic or developmental effects. The potential risk in humans is unknown.


    Bictegravir with emtricitabine and tenofovir alafenamide is contraindicated during breastfeeding.

    Use of bictegravir with emtricitabine and tenofovir alafenamide is contraindicated by the manufacturer. Animal data reports bictegravir with emtricitabine and tenofovir alafenamide in the breast milk, emtricitabine has found to be present in human breast milk. Effects on exposed infants are unknown.

    Side Effects

    Abdominal pain
    Autoimmune disorders
    Autoimmune hepatitis
    Behavioural disturbances
    Dream abnormalities
    Graves' disease
    Metabolic disorders
    Sleep disorders
    Stevens-Johnson syndrome
    Suicidal tendencies


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2021

    Reference Sources

    Summary of Product Characteristics: Biktarvy 50mg/200mg/25mg film-coated tablets. Gilead Sciences Ltd. Revised September 2021.

    NICE Evidence Services Available at: Last accessed: 03 November 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.